Published on:

New Diabetes Drug May Lead to Bladder and Breast Cancer

Dapagliflozin, a new experimental diabetes drug, is already under scrutiny for possibly causing cancer. The drug has not even hit the market yet, however, if approved, it would be the first in a new line of diabetes drugs that treat type 2 diabetes by eliminating access sugar in the urine. Unfortunately, bladder and breast cancer side effect concerns may prevent the drug from ever being sold. Based on the clinical research that our defective drug lawyers reviewed, the new diabetes drug is strikingly similar to other defective diabetes drugs that have led to numerous drug injury lawsuits, posing a serious health risk for consumers.

Dapagliflozin would be a new option for diabetes patients that typically turn to diabetes drugs to reduce the amount of sugar they absorb from food. The drug is being developed by Bristol-Myers Squibb and AstraZeneca, and other major manufacturers such as Johnson & Johnson and Eli Lilly are pursing similar drugs. Unfortunately, the drug’s safety and effectiveness is creating major concerns.